Ovarian Cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to announce it has completed the final development and preparation activities required to commence Analytical Validation (AV), marking the Company's transition into the formal phase of data collection ahead of FDA submission.

Ovarian Cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to announce that it has now achieved its recruitment target with 514 blood samples collected for its pivotal U.S. clinical trial, marking completion of a key milestone in the Company’s clinical, regulatory and commercialisation pathway.

23rd March 2026: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to announce it has optimised the biomarker panel underpinning its Pre-Surgical Ovarian Cancer Test, expanding from five to eight biomarkers to support commercial-scale deployment and regulatory progression.